Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot
cohort of human recurrent malignant glioma patients. All patients will have been previously
treated with the standard-of-care treatment which includes surgical resection, radiation and
chemotherapy, and in some cases treatment for recurrent disease with investigational agents
or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established
by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic
acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on
this protocol.